Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Ann Oncol
; 17 Suppl 5: v153-7, 2006 May.
Article
en En
| MEDLINE
| ID: mdl-16807446
ABSTRACT
BACKGROUND:
Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option. PATIENTS ANDMETHODS:
Clinical trials for biliary and hepatic carcinoma have been reviewed.RESULTS:
We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m(2) d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3-4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Biliar
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Carcinoma Hepatocelular
/
Desoxicitidina
/
Neoplasias Hepáticas
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2006
Tipo del documento:
Article